Biomarker Panel for Substance Use Disorder Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means for detecting, diagnosing, or predicting substance use disorders, which are complex diseases causing significant health issues worldwide, with no reliable therapy or diagnosis available.
Innovation Solution
The use of biomarkers such as NFL, CCL11, Nectin-4, MPO, and ADAM10 in biological samples to indicate neurotoxicity, chronic stress, skin irritation, alcohol dependence, and synaptopathy, respectively, for early detection and monitoring of substance use disorders, and IP-10, CDH2, IL-7, and Caspase-10 for detecting infections like hepatitis virus or human immunodeficiency virus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods are used for substance use disorders, then the diagnosis process is simple and quick, but the accuracy and reliability of detection is insufficient
Solution Approach 1:
The patent segments the diagnostic process into multiple independent biomarker detections (NFL, CCL11, Nectin-4, MPO, ADAM10), each targeting specific aspects of substance use disorders. This segmentation allows for more precise detection of different disease manifestations while maintaining modular testing approaches that can be implemented systematically.
Solution Approach 2:
The patent develops a universal biomarker panel that can detect multiple types of substance use disorders (alcohol, opioids, ketamine, stimulants) simultaneously. This multi-functional diagnostic approach improves detection accuracy across different substance types without requiring separate diagnostic protocols for each substance class.
2Reliability
If no biomarker-based methods are used, then the diagnostic approach remains simple, but the ability to predict treatment response and prognosis is lacking
Solution Approach 1:
The patent measures biomarker levels before treatment initiation to predict treatment response and prognosis in advance. By performing these measurements preliminarily, clinicians can select appropriate treatment strategies and monitor expected outcomes, improving treatment reliability without adding complex ongoing monitoring requirements.
Solution Approach 2:
The patent uses biomarkers as intermediary indicators that mediate between treatment intervention and clinical outcomes. These biomarkers serve as measurable proxies for complex biological processes, making treatment response and prognosis detectable through standardized laboratory methods rather than direct clinical observation.
3Loss of time
If comprehensive biomarker panels are implemented, then early detection and monitoring capability is improved, but the cost and complexity of testing increases
Solution Approach 1:
The patent combines multiple biomarker detections into a single integrated testing panel, allowing simultaneous measurement of NFL, CCL11, Nectin-4, MPO, and ADAM10 levels. This merging approach enables comprehensive early detection and monitoring in one test rather than requiring multiple separate assays, reducing overall detection time while managing complexity through standardized panel implementation.
Data Source
AI summary
The disclosure provides methods of using biomarkers to predict risk or likelihood and/or prognosis of and/or detect or diagnose substance use disorders or infections and/or monitor progress of substance use disorders and infections.